Cytodyne to appeal lawsuit
This article was originally published in The Tan Sheet
Executive Summary
Xenadrine marketer will appeal class action ruling by San Diego state court May 30 that firm's ads for ephedra-containing Xenadrine RFA-1 are false, deceptive. Judge Ronald Styn ordered firm to pay $12.5 mil. to California consumers because it is "money obtained by means of unlawful practice." Ruling maintains Cytodyne's "before and after" testimonies are misleading, exaggerate individual results. In response, firm states "we believe California's false advertising laws are so lax that they literally permit any business that advertises a product to be sued - even when, as here, the plaintiff's lawyer doesn't have an injured or deceived client." Plaintiff's lawyer Todd Macaluso of San Diego-based Macaluso & Associates reportedly also will represent parents of Steve Bechler in suit against Cytodyne...
You may also be interested in...
Cytodyne Products’ Distribution And Sales Rights Licensed To Phoenix Labs
Cytodyne Technologies has licensed the distribution, marketing and sales rights to its products to Apex Fitness Group's Phoenix Labs division, the firms announced June 16
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.